Results 101 to 110 of about 1,738 (148)

Epidemiology of chronic lymphocytic leukaemia in Germany: A retrospective analysis of administrative claims data. [PDF]

Ann Hematol
Maqhuzu PN, Bocuk D, Boelz S, Hosseini SK, Leeb C, Renevey F, Mevius A, Greth K, Christofyllakis K.   +8 more
europepmc   +1 more source

First Line Therapy in Mantle Cell Lymphoma-The Role of BTKi in the Initial Treatment of Transplant-Eligible and -Ineligible Patients. [PDF]

Hematol Oncol
Silkenstedt E, Dreyling M.
europepmc   +1 more source

Cost impact of Bruton's tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia. [PDF]

J Comp Eff Res
Kittai AS, Patel DA, Shafrin J, Zawadzki N, Shetty VS, Barqawi YK, Rhodes JM.   +6 more
europepmc   +1 more source

Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation Agents. [PDF]

Am J Cardiovasc Drugs
Spadafora L, Russo F, Bukowska-Olech E, Panichella G, Garofalo M, Cacciatore S, Sabouret P, Sarto G, Simeone B, Rocco E, Lauretti A, Versaci F, Zoccai GB, Colaiori I, Valenti V, Sciarretta S, Bernardi M.   +16 more
europepmc   +1 more source

Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? [PDF]

Eur J Haematol
Caserta S, Martino EA, Vigna E, Bruzzese A, Amodio N, Lucia E, Olivito V, Labanca C, Mendicino F, Morabito F, Gentile M.   +10 more
europepmc   +1 more source

Considerations for the practical management of cardiovascular risk with Bruton's tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia. [PDF]

Oncologist
Lenihan D, Bloom M, Copeland-Halperin R, Fleming MR, Fradley M, O'Quinn R, Bhat SA.   +6 more
europepmc   +1 more source

Sustained remission with PD-1 and BTK inhibitors maintenance after chimeric antigen receptor T-cell therapy in CNS lymphoma. [PDF]

Cancer Immunol Immunother
Yu L, Ping N, Zou R, Zhu Q, Li J, Zhang X, Xia F, He J, Tu J, Kong D, Wu D, Jin Z, Qu C.   +12 more
europepmc   +1 more source

Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors. [PDF]

Intern Med J
Anderson MA, Awan FT, Berkahn L, Crassini K, Lee HP, Marlton P, Mulligan SP, Nolan M, Tam C, Sverdlov AL.   +9 more
europepmc   +1 more source

Zanubrutinib in the treatment of Waldenström Macroglobulinemia. [PDF]

Future Oncol
Goodall E, Opat S.
europepmc   +1 more source

Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study. [PDF]

Blood Adv
García-Sanz R, Owen RG, Jurczak W, Dimopoulos MA, McCarthy H, Cull G, Opat SS, Castillo JJ, Kersten MJ, Wahlin BE, Grosicki S, Prathikanti R, Tian T, Allewelt H, Cohen AC, Tam CS.   +15 more
europepmc   +1 more source